Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, ...

In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On the other hand, the Dow registered a loss of 0.09%, and the ...

Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7, UBS initiated coverage of ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

An overview of Pfizer within the biopharmaceutical sector, covering research, manufacturing, global distribution, and index ...

At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...

Pfizer Inc. (NYSE:PFE) ranks among the best stocks under $25 to buy now. Citing the company’s cautious 2026 outlook, BMO ...

CHONGQING, CHINA - APRIL 23: In this photo illustration, the logo of Pfizer Inc. is displayed on a smartphone screen, with a stock market chart visible in the background, reflecting trading activity ...